On December 24, the Shijiazhuang City Top 100 Enterprises Summit 2019 was held, and the "Shijiazhuang City Top 100 Enterprises" list was released. CSPC ranked strong and ranked fifth.
The ranking of the top 100 enterprises in Shijiazhuang in 2019 was carried out by the Shijiazhuang Enterprise Federation and the Entrepreneurs Association in accordance with the requirements of the China Enterprise Federation. The purpose is to comprehensively and accurately reflect the development strength and level of the city's enterprises, stimulate the entrepreneurial innovation of the vast number of enterprises, strengthen the source of strength for excellence, and achieve high-quality development.
In accordance with the internationally accepted ranking method, the working group ranked the top 100 enterprises in Shijiazhuang City based on the sales revenue (or operating income) indicators of the enterprises in the previous year.
"Top 100 enterprises are the vanguard of our city's enterprises, and are an important force to promote high-quality development of Shijiazhuang's economy." Shijiazhuang City Enterprise Confederations and entrepreneurs associations said that at present, Shijiazhuang is building a "4 + 4" The development pattern of modern industry, I hope that the top 100 companies will further seize opportunities, continue to promote scientific and technological innovation, increase project investment, accelerate transformation and upgrading, continue to strengthen large-scale advantages, innovation advantages, brand advantages, and continuously improve development quality and efficiency, and jointly support Shijiazhuang The backbone of the economy.
In 2018, CSPC achieved sales revenue of RMB 30.068 billion and paid various taxes of RMB 2.76 billion, making outstanding contributions to the development of China's pharmaceutical industry and regional economic construction. With scientific research and innovation as the driving force, CSPC has realized the transformation and upgrading from general drug operation to innovative drug operation. It has continued to increase research investment, upgrade the level of intelligent manufacturing, and strictly control product quality. Level innovative enterprise.
As the vanguard of Shijiazhuang's biomedical health industry, CSPC also turns its eyes to international. On December 20, CSPC's internationalization process broke through again. Xuanning was first approved by the US Food and Drug Administration for listing. This means that the product has obtained a license for global marketing and the blood pressure developed by China. New drugs have become international standards.
In the future, CSPC will be led by innovation, committed to building the “hard core” of Chinese pharmaceutical companies in the international market, committed to providing the best medicines for global patients, building a modern provincial capital, a strong economic city, and promoting national biomedicine Industrial development and make greater contributions.